

**PATENT**

I hereby certify that on December 14, 2006, which is the date I am signing this certificate, I am transmitting this correspondence and all identified attachments electronically to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
/Andrew Lee/  
Andrew Lee

Applicant: Jong-Gu Park et al.  
Serial No.: 10/634,408  
Filed: August 5, 2003  
Title: **NEPHRITIS TREATMENT BY  
GENE THERAPY**  
Examiner: Kelly, Robert M.  
Art Unit: 1633  
Attorney Docket No.: 57354-08USA

**IN THE UNITED STATES OF AMERICA PATENT OFFICE**

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached form PTO/SB/08B (substitute for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents were submitted together with an Information Disclosure Statement on August 5, 2003. This Information Disclosure Statement is submitted to correct the previously filed Information Disclosure Statement filed on August 5, 2003. This Information Disclosure Statement includes titles of the references which were missing in the original submission.

English Language Documents:

Kamanna et al., "Hyperlipidemia and kidney disease: Concepts derived from histopathology and cell biology of the glomerulus," <i>Histol Histopathol</i> , 13:169-179 (1998).
Del Prete et al., "Molecular Biology of Diabetic Glomerulosclerosis," <i>Nephrol Dial Transplant</i> , 13(8):20-25 (1998).
Wehrmann et al., "Long-term prognosis of focal sclero-Sing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes," <i>Clinical Nephrology</i> , 33(3):115-122 (1990).
Mackensen-Haen et al., "The consequences for renal function of widening of the interstitium and changes in the tubular epithelium of the renal cortex and outer medulla in various renal diseases," <i>Clinical Nephrology</i> , 37(2):70-77 (1992).
Kitching et al., "Interleukin-4 and interleukin-10 attenuate established crescentic glomerulonephritis in mice," <i>Kidney International</i> , 52:52-59 (1997).
Rui-Mei et al., "Dysregulation of cytokine expression in tubulointerstitial nephritis associated with murine malaria," <i>Kidney International</i> , 53:845-852 (1998).
Fiorentino et al., "Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones," <i>J Exp Med</i> , 170:2081-2095 (1989).
De Waal Malefyt et al., "Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression," <i>J Exp Med</i> , 174:915-924 (1991).
Irwin et al., "Effects of enalapril on adriamycin-induced nephrosis," <i>Pediatr Nephrol</i> , 6:448-450 (1992).
Taal et al., "Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney," <i>Kidney International</i> , 58:1664-1676 (2000).
Chen et al., "Alterations of glomerular and extracellular glutathione peroxidase levels in patients and rats with focal segmental glomerulosclerosis," <i>J Lab Clin Med</i> , 137:279-283 (2001).
Ratschek et al., "Decompensated benign nephrosclerosis and secondary malignant nephrosclerosis," <i>Clin Nephrol</i> , 25:221-226 (1986).
Bohle et al., "Is there any tubular secretion of protein?," <i>Clin Nephrol</i> , 29(1):28-34 (1988).
Engelhardt et al., "Interleukin-10 and Phenomena of Tolerance in Interleukin-2 Therapy," <i>J Clin Oncol</i> , 14:1405 (1996).
Matsumoto et al., "Spontaneous and lipopolysaccharide-stimulated secretion of cytokines by peripheral blood monocytes in IgA nephropathy is inhibited by interleukin-10," <i>Nephron</i> , 73:305-309 (1996).
Go et al., "Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells," <i>J Exp Med</i> , 172:1625-1631 (1990).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning copies of the attached form PTO/SB/08B (substitute for form 1449/PTO) with initials or other appropriate marks, and that the references be made of record as cited references in the application.

Respectfully submitted,

December 14, 2006  
Date

By: /Joseph Hyosuk Kim/  
Joseph Hyosuk Kim, Ph.D.  
Reg. No. 41,425  
Attorney for Applicants

**JHK Law**  
P.O. Box 1078  
La Canada, CA 91012-1078  
Telephone: (818) 952-7430  
Facsimile: (818) 952-7424

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/634,408
		Filing Date	August 5, 2003
		First Named Inventor	Jong-gu PARK
		Art Unit	1633
		Examiner Name	Kelly, Robert M.
Sheet 1	of 2	Attorney Docket Number	57354-08USA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	KAMANNA et al., "Hyperlipidemia and kidney disease: Concepts derived from histopathology and cell biology of the glomerulus," Histol Histopathol, 13:169-179 (1998).	
	C2	DEL PRETE et al., "Molecular Biology of Diabetic Glomerulosclerosis," Nephrol Dial Transplant, 13(8):20-25 (1998).	
	C3	WEHRMANN et al., "Long-term prognosis of focal sclero-Sing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes," Clinical Nephrology, 33(3):115-122 (1990).	
	C4	MACKENSEN-HAEN et al., "The consequences for renal function of widening of the interstitium and changes in the tubular epithelium of the renal cortex and outer medulla in various renal diseases," Clinical Nephrology, 37(2):70-77 (1992).	
	C5	KITCHING et al., "Interleukin-4 and interleukin-10 attenuate established crescentic glomerulonephritis in mice," Kidney International, 52:52-59 (1997).	
	C6	RUI-MEI et al., "Dysregulation of cytokine expression in tubulointerstitial nephritis associated with murine malaria," Kidney International, 53:845-852 (1998).	
	C7	FIorentino et al., "Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones," J Exp Med, 170:2081-2095 (1989).	
	C8	DE WAAL MALEFYT et al., "Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression," J Exp Med, 174:915-924 (1991).	
	C9	IRWIN et al., "Effects of enalapril on adriamycin-induced nephrosis," Pediatr Nephrol, 6:448-450 (1992).	
	C10	TAAL et al., "Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney," Kidney International, 58:1664-1676 (2000).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/634,408
		Filing Date	August 5, 2003
		First Named Inventor	Jong-gu PARK
		Art Unit	1633
		Examiner Name	Kelly, Robert M.
Sheet 2	of 2	Attorney Docket Number	57354-08USA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C11	CHEN et al., "Alterations of glomerular and extracellular glutathione peroxidase levels in patients and rats with focal segmental glomerulosclerosis," J Lab Clin Med, 137:279-283 (2001).	
	C12	RATSCHEK et al., "Decompensated benign nephrosclerosis and secondary malignant nephrosclerosis," Clin Nephrol, 25:221-226 (1986).	
	C13	BOHLE et al., "Is there any tubular secretion of protein?," Clin Nephrol, 29 (1):28-34 (1988).	
	C14	ENGELHARDT et al., "Interleukin-10 and Phenomena of Tolerance in Interleukin-2 Therapy," J Clin Oncol, 14:1405 (1996).	
	C15	MATSUMOTO et al., "Spontaneous and lipopolysaccharide-stimulated secretion of cytokines by peripheral blood monocytes in IgA nephropathy is inhibited by interleukin-10," Nephron, 73:305-309 (1996).	
	C16	GO et al., "Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells," J Exp Med, 172:1625-1631 (1990).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.